Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/104659

Beta release

Statistics of Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
Statistics for this year
PeriodVisitsDownloads
202400
Statistics for the last 3 months
PeriodVisitsDownloads
2024-0700
2024-0800
2024-0900